(19)
(11) EP 2 938 351 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
31.07.2019 Bulletin 2019/31

(45) Mention of the grant of the patent:
26.06.2019 Bulletin 2019/26

(21) Application number: 13867801.6

(22) Date of filing: 23.12.2013
(51) International Patent Classification (IPC): 
A61K 38/00(2006.01)
C12N 9/64(2006.01)
 A61K 38/48(2006.01)
(86) International application number:
PCT/US2013/077405
(87) International publication number:
WO 2014/105784 (03.07.2014 Gazette 2014/27)

(54)

SHORT-ACTING FACTOR VII POLYPEPTIDES

KURZFRISTIG WIRKENDE FAKTOR-VII-POLYPEPTIDE

POLYPEPTIDES DE FACTEUR VII À COURTE ACTION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 24.12.2012 US 201261745674 P
15.03.2013 US 201361787026 P

(43) Date of publication of application:
04.11.2015 Bulletin 2015/45

(60) Divisional application:
16196780.7 / 3165232
19181784.0

(73) Proprietor: Coagulant Therapeutics Corporation
Seoul (KR)

(72) Inventors:
  • BAUZON, Maxine
    Hercules, California 94547 (US)
  • HERMISTON, Terry
    Mill Valley, California 94941 (US)

(74) Representative: Greaves Brewster LLP 
Copa House Station Road
Cheddar, Somerset BS27 3AH
Cheddar, Somerset BS27 3AH (GB)


(56) References cited: : 
WO-A1-03/093465
WO-A2-2006/114105
 WO-A1-2007/013993
US-A1- 2010 028 939
   
  • SEESTED TORBEN ET AL: "The unsialylated subpopulation of recombinant activated factor VII binds to the asialo-glycoprotein receptor (ASGPR) on primary rat hepatocytes", THROMBOSIS AND HAEMOSTASIS, SCHATTAUER GMBH, DE, vol. 104, no. 6, 10 December 2010 (2010-12-10), pages 1166-1173, XP008139984, ISSN: 0340-6245, DOI: 10.1160/TH10-06-0356
  • APPA RUPA S ET AL: "Investigating clearance mechanisms for recombinant activated factor VII in a perfused liver model", THROMBOSIS AND HAEMOSTASIS, SCHATTAUER GMBH, DE, vol. 104, no. 2, 1 August 2010 (2010-08-01), pages 243-251, XP009156273, ISSN: 0340-6245
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).